This item was submitted to [Loughborough's Research Repository](#) by the author.
Items in Figshare are protected by copyright, with all rights reserved, unless otherwise indicated.

Hydroxypropyl methylcellulose as a novel tool for isothermal solution crystallization of micronized paracetamol

PLEASE CITE THE PUBLISHED VERSION

<http://dx.doi.org/10.1021/cg4009637>

PUBLISHER

© 2014 American Chemical Society

VERSION

AM (Accepted Manuscript)

PUBLISHER STATEMENT

This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at:
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

LICENCE

CC BY-NC-ND 4.0

REPOSITORY RECORD

Reis, Nuno M., Zizheng K. Liu, Cassilda Reis, and Malcolm R. Mackley. 2015. "Hydroxypropyl Methylcellulose as a Novel Tool for Isothermal Solution Crystallization of Micronized Paracetamol". figshare.
<https://hdl.handle.net/2134/18358>.

**HPMC as a novel tool for isothermal solution crystallisation of micronized
Paracetamol**

Nuno M Reis^{a,b,*}, Zizheng K Liu^a, Cassilda M Reis^a, and Malcolm R Mackley^a

*^aDepartment of Chemical Engineering and Biotechnology, University of Cambridge, New Museums
Site, Pembroke Street, Cambridge CB2 3RA, UK*

^bDepartment of Chemical Engineering, Loughborough University, Loughborough LE11 3TU, UK

* Corresponding author: Phone +44 (0) 1509 222 505; Fax +44 (0) 1509 223 923; e-mail n.m.reis@lboro.ac.uk

HPMC as a novel tool for isothermal solution crystallisation of micronized Paracetamol

Nuno M Reis^{a,b,†}, Zizheng K Liu^a, Cassilda M Reis^a, and Malcolm R Mackley^a

^a*Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK*

^b*Department of Chemical Engineering, Loughborough University, Loughborough LE11 3TU, UK*

Abstract

Pulmonary inhalation is increasingly being selected as a preferred route for the delivery of both small and large drug macromolecules for the treatment of a range of pathologies. The direct crystallisation of micronized powders, in particular Paracetamol remains difficult, as it requires the ability to work in high solution supersaturations where agglomeration, wall crusting and heterogeneous nucleation hinders the control of crystal size and crystal size distribution. Polymer additives are recognised to help driving the production of a given polymorph or controlling crystal shape by means of adsorption on crystal surface. With the aim of exploiting the polymer-control nucleation and growth of crystals for enhanced direct crystallisation of micronized powders, batch cooling crystallisation of Paracetamol in water was carried out in the presence of 0.1-0.8% w/w hydroxypropyl methylcellulose (HPMC). In the presence of polymer the onset of nucleation was delayed and extended beyond the cooling time of the solution, resulting in an isothermal cooling crystallisation and the production of micronized Paracetamol with a mean crystal size D_{50} , in the range of 15-20 μm and an improved crystal size distribution. Equally, the rate generation of solution cloudiness was reduced by over 3-fold for the highest HPMC concentration tested, with no detectable impact on final product yield. The mechanisms for nucleation delay and growth inhibition by HPMC is unknown, however a modification of crystal's shape observed upon the addition of HPMC to the solution suggested it might be related to mass transfer limitations and inter-molecular hydrogen bounding between the large HPMC and the small drug molecules. This technique can potentially be used for direct crystallisation of other micronized drugs.

Keywords: Paracetamol, micronized, cooling crystallisation, isothermal crystallisation, HPMC

[†] Corresponding author: Phone +44 (0) 1509 222 505; Fax +44 (0) 1509 223 923; e-mail n.m.reis@lboro.ac.uk

Introduction

Pulmonary inhalation is being increasingly selected as a preferred route for the delivery of both small and large drug macromolecules for the treatment of a range of pathologies. The fast expanding dry powder inhalers (DPI) market is expected to reach over US\$13bn per annum by 2016, benefiting from the remarkable development in drug formulation and inhalation device designs mainly in recent years.¹ Despite such technological advancement, the production of micronized ($\sim 1\text{-}10\text{ }\mu\text{m}$) active pharmaceutical ingredients (APIs) still relies on traditional milling and grinding techniques for size reduction of crystals. These methods apply high energy that result in a final product with broad size distribution, limited crystallinity and poor flowing properties with limited dispersability.² An alternative technique that is in increasing adoption by industry is spray drying.³ It allows producing micronized APIs of desirable size however particles are amorphous and have a larger tendency to re-crystallise or degrade.² It is therefore recognised that direct crystallisation of micronized crystals solution is advantageous, however producing small crystal sizes requires operation with the high supersaturations at which the control of agglomeration, wall crusting, crystal size and crystal size distribution (CSD) becomes extremely challenging.⁴

Crystallisation is an important process in the chemical, pharmaceutical, biotechnological and allied industries, as it is used extensively for separation and purification of organic fine chemicals or APIs and production of micro-sized APIs for drug delivery.⁵ Important product characteristics such as crystal size, CSD, and crystal morphology are determined by the operating conditions during the crystallization process, which include: supersaturation, temperature profiling, the presence of additives, air-water interface, anti-solvent addition rate, fluid mixing, residence time, materials of crystalliser, and agglomeration/breakage phenomena.

Stagnant crystallisation experiments have shown that polymers and other additives can help driving the production of a given polymorph,⁶⁻⁹ reducing the crystal size¹⁰ or controlling the crystal shape.⁹ The list of polymers tested is extensive and includes both hydrophilic and hydrophobic powders, such as ethylcellulose, methylcellulose (CM), polyethylene glycol (PEG), polyvinyl alcohol (PVA), agar, gelatine, polyvinyl pyrrolidone (PVP), poly(ethylene oxide) (PEO), corn starch, carrageenan, polyethylene (PE), polyvinyl chloride (PVC), polymethyl methacrylate (PMMA) and hydroxypropyl methylcellulose (HPMC) to name a few.^{3, 8-12} Generally, crystallisation additives are effective in producing polymorphs of pharmaceuticals while avoiding others by encouraging the growth of a desirable form or disrupting the growth of the other form.^{8, 9, 13, 14} Modification of crystal shape occurs as the polymer deposition on the crystal surface inhibits the growth of specific surfaces of the crystal.¹³ Reduction of particle size by means of long molecular weight additives was only marginally reported in the literature, and exception is perhaps the work of Femi-Oyewo and

Spring¹⁰, although a recent work by Xie *et al.*¹² showed that salbutamol sulphate crystal size was reduced to less than 10 μm upon presence of polymer additives HPMC, polyvinylpyrrolidone (PVP K25), lecithin and Span 85 during anti-solvent water-ethanol crystallisation.

There is also very few studies touching the effect of organic polymers in the kinetics of crystallisation. An exception is the work of Raghavan *et al.*¹⁵ who have studied anti-solvent crystallisation of hydrocortisone acetate (HA) in the presence of four different polymers (HPMC, PVP, MC and PEG400). In the absence of solution additive, the nucleation of HA was observed to be spontaneous; however in the presence of a polymer the nucleation was delayed by several hours and a level of growth inhibition of HA was observed. The mechanism of nucleation retardation was explained by the authors in terms of association of HA with the polymer through hydrogen bonding whilst the growth inhibition was related to the adsorption of polymer to the surface of the crystal.

HPMC is a natural polymer extensively used in the pharmaceutical industry as a tableting ingredient and as a binder¹⁶ because of its regulatory approval status. Steckel *et al.*² have shown that HPMC can act as a stabilising hydrocolloid during the production of micronized fluticasone-17-propionate by spray drying, resulting in one order of magnitude reduction in particle size.

In this work small concentrations of HPMC were used for manipulating the kinetics of cooling crystallisation of Paracetamol, which offered a new level of control over the nucleation and crystal growth under well mixed conditions and allow reduced crystal size and improved CSDs. The mean crystal size, CSD and crystal morphology have been experimentally evaluated for a concentration of HPMC in range of 0 - 0.8% w/w using standard powder characterisation techniques.

Experimental section

Materials

Paracetamol or acetaminophen (CAS number, 103-90-2, min 99% purity) and HPMC (CAS 9004-65-3, typical MW = 10,000) were supplied by Sigma-Aldrich, Inc (Dorset, UK).

Crystallisation procedure

Paracetamol was crystallised in water by dissolving a given amount of Paracetamol at 70 °C corresponding to a saturated solution at 65 °C, and rapidly cooling it to room temperature (20 °C). For each experiment, 3.0 grams of Paracetamol were dissolved in 60 grams of deionised water in the presence of 0-0.8% w/w of HPMC (percentage of mass of HPMC per mass of water), giving a maximum drug to polymer ratio of 6.25:1 in weight or 413:1 in molar basis. The crystallisation vessel consisted of 42 mm internal diameter, d , glass-jacketed unbaffled tank with a liquid height, $h = d$ corresponding to a working volume of 60 ml (Figure 1). The solution was magnetically stirred

at 70 °C for 1 hour to ensure complete dissolution of Paracetamol, by circulating hot water (HAAK, Fisons DCS B3, Pacific Diagnostic, Inc. USA). The maximum working volume of the tank was 83 ml, and all experiments were done in the presence of a free surface. Mixing was provided using an 18 mm length magnetic stirrer at 300 rpm, controlled by a stirrer plate (KIKA, Labortechnik, Janke & Kunkel GmbH & Co KG. UK).

The Paracetamol solubility estimated from Granberg&Rasmuson¹⁹ for working temperature of 65 °C and 0% HPMC was ~48.3 grams per kilogram of water, i.e. ~2.9 grams per 60 ml of water.

The cooling crystallisation was started by quickly switching circulating hot water in a 3-way valve to chilled water at 20 ± 0.1 °C from a refrigerated/cooling circulator (Grant LTD20, Cambridge, UK), which induced a rapid temperature quenching in the crystallisation vessel. The experiments were continued for about 45 minutes from the start of the cooling process, which was found sufficient to complete of crystals growth and fully deplete supersaturation in the solution. The supersaturation ratio of pure paracetamol solution defined as $S = C/C^*$ was estimated as equal to 3.8 based on the solubility data for pure paracetamol reported by Granberg&Rasmuson.¹⁹ The initial paracetamol concentration remained constant for all HPCM concentrations tested.

The crystallisation vessel was equipped with a thermocouple (TME 2050, k-type) and a reflectance fibre optical probe for on-line monitoring of the temperature and turbidity of crystallisation solution, respectively (Figure 1). Details of the optical probe are given in section 2.3.

At the end of each crystallisation run, the slurry was vacuum filtered through a 0.2 µm cut-off PTFE membrane (Whatman Inc, USA) and the crystals washed with 3*1.5 ml of deionised water at room temperature. Paracetamol crystals were then dried in a desiccator for about 12 hours after which the dry weight was determined in an analytical balance. The crystal size and CSD were then characterised using an automated optical microscopy system, and crystal morphology analysed by Scanning Electron Microscopy (SEM). Crystal system was identified using powder X-ray diffraction (XRD) and the thermal behaviour using Differential Scanning Calorimetry (DSC) techniques.

Monitoring of solution turbidity

Solution cloudiness or turbidity was monitored real-time using a reflectance optical fibre probe. The optical probe (FCR 7UV200, Avantes, Eerbeek, Netherlands) consisted of 6×200 µm diameter optical fibres carrying the light from a deuterium halogen light source and a 7th fibre in the core of the probe delivering the scattered light to a spectrometer connected to a PC, which was controlled by Avasoft (Avantes, Eerbeek, Netherlands). The probe was inserted through the lid of the crystalliser at a certain angle to avoid direct reflection from the walls of the crystalliser. The crystalliser was fully covered with aluminium foil to impede interference of environment light. The

reflected light spectrum was continuously scanned through the experimental time, t , with a CCD spectrometer using a proper integration time. An integration function was then defined to monitor the total reflected light, I_w or the photon counts in the spectrum for a wavelength range, w , between 585 and 615 nm, where crystal particles were found to scatter light strongly:

$$R(t) = \int_{w=585nm}^{w=615nm} I_w(t) \quad (1)$$

The relative solution transmittance, $T(t)$ defined as the fraction of incident light that passed through the solution in the monitored wavelength range w , was then calculated as $T(t) = R(t)/R(t=0)$ and normalised for each experiment by assuming 100 % light transmittance at time zero, i.e. $T(t=0) = 1$ and 0% transmittance towards the end of the crystallisation, i.e. $T(t=\infty) = 0$.

Crystal characterisation

The mean crystal size and CSDs of Paracetamol powder were determined using an automatic optical system, the Morphologi G3 (Malvern Instruments, Malvern, UK). Optical microscopy offered a more robust CSD method for sizing Paracetamol crystals in comparison with laser diffraction measurements because it offers the possibility of analysing the sample in the dispersed powder form using compressed air at 1.5 barg and avoided sonication process for dispersion of crystals, which has shown to result in the partial dissolution or agglomeration of Paracetamol crystals (results not shown). Paracetamol is very prone to agglomeration, therefore CSD analysis is especially difficult. Nevertheless, the Morphologi G3 system allows the reproducible, automatic analysis of a large number of particles or crystals and the possibility of using different types of filters to manually discard large agglomerates resulting from crystal caking during the sampling and powder drying process.

For CSD analysis using Morphologi G3 1.5 mg of dry powder were loaded in 20 μm thick aluminium foil and dispersed into the clean, glass surface of the microscope using compressed air at 1.5 barg. The G3 software measured the projected area of the crystals/particles and assigned it the equivalent diameter of a circle, C_E , through a standard operating procedure (SOP). The crystal size computed this way was based on C_E^3 , which would only fit laser scattering measurements for perfectly spherical particles. A typical run comprised a sample of 5,000-10,000 crystals to ensure the statistical significance of the acquired CSD. The reproducibility of CDS measurements was found very high upon SOP optimisation (results not shown).

For SEM of the micronized powders, the dried crystals were spread over a surface and dried overnight in He atmosphere. The samples were then coated with a 20 nm thick gold coating and scanned at 5 Kev in FEI Philips XL30 FEGSEM equipped with an Oxford Instruments INCA EDX system running a 30 mm² SiLi thin window pentafet EDX detector.

The effect of HPMC on the thermal behaviour above ambient of dry Paracetamol powder was recorded using a Perkin-Elmer Pyris 1 scanning differential calorimeter. For that purpose, approximately 5 mg of sample were heated at 10 °C/min from 40 to 180 °C in perforated crimped aluminium pans while being purged with dry nitrogen. The heating and cooling cycles were performed, intercalated by 1 min holding time.

For analysis of the effect of HPMC on crystal system, powder X-ray diffractions in dried powder were acquired at room temperature on a Philips PW1820 diffractometer using Copper-k-alpha radiation (tube operated at 40 kV, 40 mA), a θ - θ goniometer, automatic divergence and 0.2 mm receiving slits, a silicon secondary monochromator, and a scintillation counter. The XRD trace was scanned in 2θ from 5° to 60°, at a rate of 0.050° of 2θ per 2 seconds. The powder samples were prepared as flat surfaces in aluminium sample holders.

Results and discussion

Effect of HPMC on the kinetics of Paracetamol crystallisation

Paracetamol was crystallised in water in a small batch stirred glass vessel containing a reduced HPMC concentration, by quickly dropping the temperature of a slightly undersaturated solution from 70 °C to 20 °C. Turbidity was on-line monitored during the cooling process using an optical microprobe immersed in the solution, which allowed sensitive detection of the onset of nucleation and quantitative detection of the rate of generation of cloudiness, which is ultimately linked to the generation and growth of crystals. Figure 2 shows the variation of solution temperature and relative transmittance (the lower the transmittance the higher the solution cloudiness) for a selected number of HPMC concentrations. The HPMC concentrations tested in this study were 0.0, 0.1, 0.3, 0.4, 0.7 and 0.8% w/w but only a selection of these is shown in Figure 2 for simplicity in clarity of data presented. The temperature cooling profile was highly reproducible in the whole set of experiments, therefore only one cooling curve is shown in Figure 2. HPMC effectively delayed the onset of nucleation and reduced the rate of generation of cloudiness in the solution as can be confirmed from the plots. With pure Paracetamol, a shower of crystals was detected within 1-2 minutes, and 90% of the solution cloudiness generated within the following minute, and crystal growth was completed within 5 minutes from the beginning of the cooling process, which compares well with the cooling time of the solution in the vessel. In the presence of HPMC, the time of onset of nucleation extended to up to 9 minutes depending on the HPMC concentration, so well beyond the cooling time of the solution in the vessel. This ultimately means that the crystallisation in the presence of HPMC occurs entirely under full isothermal conditions, at which the solution supersaturation is at its maximum and therefore a shower of crystals beneficial for the production of micronized powders is expected. The ability of running solution crystallisations in full isothermal conditions as shown in

1 this manuscript is novel and might find broad applications in the direct crystallisation of micronized
2 APIs.
3

4
5 The turbidity profiles in Figure 2 did not allow the full deconvolution of crystal nucleation and
6 crystal growth rates, however some quantitative information was extracted in order to quantify the
7 effect of polymer additive in the overall batch cooling crystallisation kinetics. For that purpose, an
8 arbitrary induction time, t_{ind} and crystal growth completion time, t_G were defined corresponding to
9 the time required to give a 20% and 80% decrease, respectively, in solution transmittance. For this
10 analysis the whole range of HPMC concentrations tested was considered. Equally, a maximum
11 generated cloudiness rate, R_c , was calculated from the initial gradient of relative solution
12 absorbance versus cooling time, which is summarised in Figure 3a. During the initial stage of
13 crystal growth, when submicron nuclei grow to a size to be optically detected and therefore the
14 concentration of crystals is proportional to the absorbance of the solution, the increase in solution
15 absorbance (defined as $-\log_{10}$ of transmittance) is essentially related to the increase in the
16 concentration of particles or the formation of new crystals, therefore R_c should capture the relative
17 effect of polymer additive concentration on kinetics of crystal nucleation. Figure 3a showed that t_{ind}
18 increased by up to 5.4-fold and t_G by up to 9.5-fold upon the addition of HPCM to the solution, with
19 the maximum effect being observed at the highest HPMC concentration tested of 0.8% w/w.
20 Equally, R_c decreased up to 73.4% with increasing HPMC concentration, being the inhibitory effect
21 more noticeable at low HPMC concentrations. This represents a major effect of polymer additive in
22 respect to the overall kinetics of crystallisation, from where a major reduction in crystal size could
23 be expected.
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Effect of HPMC on mean crystal size and CSD

38
39 A common motivation for controlling crystallisation processes in pharmaceutical industries is the
40 production of uniform particle sizes with a given mean crystal size. Therefore, the Paracetamol
41 powder produced in the presence of different HPMC concentrations has been characterised in
42 respect to particle size using the Morphologi G3 system, which applies compressed air for
43 dispersing dry powders on a glass microscope slide and advanced imaged analysis to determine a
44 circle equivalent diameter, C_E of the crystals. This allowed confirming that the presence of HPMC
45 in the initial crystallisation solution resulted in a significant reduction in the mean crystal size, D_{50}
46 and an improvement in CSD as shown in Figures 4a and 4b. With pure Paracetamol the D_{50}
47 obtained was 39.6 μm . This was *per se* considerably smaller than the mean sizes reported by other
48 authors for batch cooling crystallisation from solution. For example, Chew *et al.*¹⁷ and Fujiwara *et*
49 *al.*⁵ reported a D_{50} in the range of 100-250 μm for batch crystallisers, and Zarkadas & Sirkar¹⁸
50 produced crystal sizes with 50-150 μm in a continuous hollow fibre device. The smaller crystal
51
52
53
54
55
56
57
58
59
60

sizes obtained in this study are related to the large surface area-to-volume ratio of the glass vessel used in the crystallisation runs, which delivered high cooling rates for high supersaturation and nucleation rates that cannot be mimicked in larger crystallisers. Nevertheless, the CSD in Figure 4a was broad as can be seen from the great deviation of the values represented by percentile 10, $D_{10} = 15.5 \mu\text{m}$ and percentile 90, $D_{90} = 62.1 \mu\text{m}$. This could be associated with the non-isothermal conditions in the crystallisation vessel at the time of onset of solution cloudiness. The addition of 0.1% w/w of HPMC resulted in D_{50} decreasing from 39.6 to 15.4 μm and the volume-based CSD becoming remarkably sharper, with $D_{10} = 8.3 \mu\text{m}$ and $D_{90} = 22.6 \mu\text{m}$. The frequency-based CSD in Figure 4b confirmed a larger number of fines in the dried powder crystallised in the presence of 0.1% w/w HPMC, and smaller number of large crystals. The dashed vertical line represents the smallest crystal size that could be detected in with the used setup with Morphologi G3. That significant decrease in the mean crystal size was confirmed by SEM images in Figures 4c and 4d (note the different scales in the SEM microphotographs).

The effect of varying initial concentrations of HPMC on particle size distribution in respect to percentile 10, D_{10} , percentile 50, D_{50} and percentile 90, D_{90} is fully summarised in Figure 3b. The use of HPMC concentrations above 0.1% w/w resulted in no further improvement in particle size reduction or CSD, and it appeared that the presence of a very small concentration of HPMC in the solution was sufficient to provide a good level of particle size control.

Another aspect that contributed to smaller crystal sizes was the fact that Paracetamol solubility decreases very quickly with HPMC content, as shown in supplementary data (Figure S1). For a 0.1% mass ratio of HPMC to Paracetamol (corresponding to approximately 0.03% w/w of HPMC in respect to mass of solution) the solubility measured at 30 °C dropped by 40%. This means that in the presence of HPMC the crystallisation is isothermal but also supersaturation is higher than for a pure Paracetamol system. This should in theory return higher crystallisation yields, and in respect to particle size control this represents enhanced supersaturation in the presence of HPMC which favours production of smaller crystals and more fines.

Overall and based on the turbimetry data, it is not possible to identify the main mechanic leading to a significant reduction in crystal size and improvement in CSD in the presence of HPMC, but it appears linked to a higher supersaturation and tighter supersaturation control resulting from the delay of onset of nucleation, higher number of fines and reduction in Paracetamol solubility.

Effect of HPMC on crystal morphology

A number of recent studies mainly performed at static conditions have linked the use of organic polymer additives with crystal polymorphism as reviewed in the Introduction section. A given crystal form can be inhibited upon the presence of polymer or “impurities”, therefore polymer

additives can induce selective production of a given polymorph.⁶⁻⁹ Equally, other studies have reported a modification of crystal habit upon the addition of polymer additives.^{8,9} Mainly with isentropic crystals like Paracetamol,²⁰ polymers can present higher selectivity to bind given faces a crystal, so selectively inhibiting the growth on a given direction. In order to test for possible effects of HPMC additive on crystal structure, Paracetamol powders were characterised regarding their thermal behaviours and X-ray diffraction patterns. Optical and electronic microscopic analysis of the crystals showed that crystals shape changed to an elongated-prismatic shape upon the addition of polymer. The DSC and XRD data in Figures 5 and 5b, respectively, confirmed that the crystalline product obtained with pure Paracetamol and 0.1% w/w of HPMC were in fact from the same crystal form I, i.e. monoclinic Paracetamol. The experimental XRD patterns of the two Paracetamol samples crystallised with 0% and 0.1% w/w of HPMC compared in Figure 4 agreed well with XRD data of e.g. Martino *et al.*²¹ and Nichols and Frampton²² by showing peaks unique to the monoclinic form I such as $2\theta = 12.025$, 15.425 and 26.475 . Also, the melting point (endothermic) at $164\text{ }^{\circ}\text{C}$ and two crystallisation (exothermic) points at $88\text{--}89^{\circ}\text{C}$ and $135\text{--}139\text{ }^{\circ}\text{C}$ shown by DSC analysis in Figure 5b also confirmed that the two samples were of the same crystal form. This confirmed that the detected difference in kinetics of crystallisation is not due to the production of a different polymorph.

Detailed SEM analysis to all Paracetamol samples revealed a side effect with the use of HPMC concentrations of 0.3% w/w and above, with extended agglomeration and a large number of cavities or holes on the crystal surface. Figure 6 shows cavities up to 100-200 nanometers in diameter that become more prominent as more HPMC was added to the solution. The reason behind the formation of these cavities is unknown, however it is suspect to be linked to the intermolecular interactions of HPMC and Paracetamol, with HPMC adsorbing the crystal surface as suggested by Thompson *et al.*²³ for Metacetamol (a small molecule with --OH groups). Using AFM and SEM, they have shown surface features in pure Paracetamol crystals between 1 and 20 nm, that changed to 15 nm steps interspersed with holes in the presence of Metacetamol.

Effect of HPMC on final product yield

The product yield calculated in terms of dried powder weight was found independent of the HPMC concentration used, and in average $59.5 \pm 1.62\%$ as shown in Figure 3c. This was slightly lower than the theoretical yield expected from pure Paracetamol (74.1%) based on the solubility data of Granberg&Rasmuson.¹⁹ Note that the addition of HPMC to the solution can only increase the theoretical yield up to a maximum of 3.6% assuming all HPMC added to the solution ends up in the dried powder. Based on the solubility data shown in Figure S1 the addition of HPMC to the crystallisation solution should have resulted in higher yield than for pure Paracetamol, as HPMC

was found to decrease significantly the solubility of Paracetamol in water. This might be related to the dissolution of some material during the sample washing or to surface poisoning. Femi-Oyewo & Spring¹⁰ reported 91% reduction on yield of Paracetamol crystallised in the presence of HPMC under static conditions, which was shown to be related to the irreversible adsorption of polymer of the surface of the crystals. This data herein reported shows that under well mixed conditions the adsorption of polymer to the surface of the crystals is reversible however it cannot entirely overcome surface poisoning that leads to the terminal size of the crystal.

Remarks on the effect of HPMC on kinetics of Paracetamol crystallisation

The mechanics for delaying the onset of nucleation and reducing the rate of solution cloudiness in cooling crystallisation of Paracetamol crystals by HPMC is still unknown, however recent studies have proposed different hypothesis spanning from inhibition of heterogeneous nucleation to increased mass transfer resistances both related to the hydrogen bounding between the polymer and Paracetamol molecules. This section offers an overview to those important mechanisms that support the possible impact of HPMC on the nucleation and/or growth of Paracetamol crystals.

Heterogeneous nucleation is thermodynamically more favourable and is known to be related to the presence of interfaces, such as crystalliser's wall, impeller or air-waste free surface. Zarkadas & Sirkar¹⁸ have found that a combination of homogeneous and heterogeneous nucleation is possible in a cooling crystallisation process of Paracetamol in water at high supersaturation ratios, i.e. $S = 3$ and above, which was the case in this present study. In order to validate this hypothesis a further set of experiments was carried out in a combination of experimental conditions that were recognised to promote heterogeneous nucleation, such is the case of stirring, glass wall material and air-water interface, as summarised in Table 1. For each crystallisation run, the time required to detect the onset of solution cloudiness was noted (in these set of experiments the induction time was determined using naked eye). It was observed that the addition of 0.1 % w/w HPMC has similar effect in respect to the delay on induction time to the removal of free surface during the crystallisation vessels, resulting in delayed induction time from 4.0 to 9-10 min. This is likely to be associated with the fact that HPMC reduced the frequency of collisions between the solute particles, which, in turn, led to the delay of nucleation. The rate for primary nucleation is linearly proportional to the diffusion coefficient⁴ of Paracetamol, having a molecular weight of 151.2 g/mol. When the diffusion is sufficiently rapid the nucleation is not diffusion controlled. This is normally the case at high values of S , and explains the very short induction time obtained with pure Paracetamol (run 1 in Table 1). Nevertheless, with the presence of HPMC in the crystallisation solution the nucleation became increasingly limited as more polymer additive is added to the solution. This was explained by Zarkadas & Sirkar¹⁸ and Tian *et al.*²⁴ based on inter-molecular

hydrogen bonding between Paracetamol and the polymer additive. HPMC has both a hydrogen bonding donor and acceptor groups on its ring structure (Figure S2), therefore showing a high H-bonding ability and network association with drug molecules as concluded from FT-IR results of Tian *et al.*²⁴ Similar conclusion was obtained by Sahoo *et al.*²⁵ using Raman spectroscopy. The last have identified intra-molecular hydrogen bonding between HPMC and Ciprofloxacin, resulting from hydroxyl OH- groups present in both polymer additive and drug molecules. Raghavan *et al.*¹⁵ has also reported strong effect of cellulose polymers on morphology of hydrocortisone acetate. This means HPMC effectively can work as a “molecular transporter” therefore limiting both the diffusivity of drug molecules and reducing the impact probability for the formation of nuclei through collisions.

The production of smaller crystals and the reported morphological changes could also be explained based on several growth-inhibition hypothesis, such as *i*) mass transfer limitations, *ii*) impurities deposition,²⁵ *iii*) polymer adsorption on the surface of the crystals, or *iv*) a combination of those. During growth some impurities can adsorb to the surface of the crystals “blocking” the active growth sites (sometimes only blocking growth of a given face of the crystal) or entirely suppresses crystal growth.²⁶ HPMC was previously shown capable of adsorbing the surface of Paracetamol crystals.⁹ This has been linked to a reduction in the growth rate of steps when compared to pure Paracetamol. Using AFM and SEM, Thompson *et al.*²³ showed that metacetamol changed the growth steps of Paracetamol and disrupting the crystal lattice by adsorbing to the surface and inducing the formation of defects or cavities in the crystal surface.

A parallel observation from Table 1 is the relevant effect of mixing and interfaces on the crystallisation of Paracetamol in respect to induction time in the presence of 0.10% w/w HPMC. Although it is difficult to separate the effect of interfaces from that of mixing, it was observed that induction time approximately doubled in the absence of headspace in the crystallisation vessel. Interfaces are known for creating temperature gradients therefore being preferential zones for nucleation. On the other hand, the removal of agitation resulted in further increased induction times (rows 6 and 7), however this is believed to be related to the lower cooling rate in unstirred vessel.

Conclusions

Batch cooling crystallisation experiments of Paracetamol in water in the presence 0.1-0.8% w/w of HPMC revealed the ability of the natural polymer additive modifying the overall kinetics of crystallisation by slowing the rate of generation of cloudiness in the solution and delaying the onset of nucleation beyond the cooling time of a crystalliser. This allowed direct production of micronized Paracetamol crystals from solution, with a D_{50} in the range of 15-20 μm and sharp CDS, which was linked to the isothermal crystallisation conditions in the presence of HPMC and

reduction of Paracetamol solubility in the presence of polymer. The observed habit change induced by the presence of HPMC suggested the polymer acted by inhibiting growth on specific surfaces of the crystals, as previously reported for other crystallisation systems. The high density of cavities observed on the surface of the crystals for higher HPMC concentrations strongly suggests that HPMC adsorbed to surface of the crystals disrupting the hydrogen bounding network. This technique can potentially be used for enhancing direct crystallisation of other micronized drugs for pulmonary drug delivery.

Acknowledgment

The authors are grateful to Dr Jeremy Skepper from Multi Imaging Centre, Cambridge, for help with SEM; Dr Eric Rees and Dr Joanna Stasiak for help with XRD; Zlatko Saracevic for help with DSC analysis, and Henrietta Adomako at Loughborough University for assistance with Paracetamol solubility experiments. NMR is grateful to Fundacao para a Ciencia e Tecnologia, FCT (SFRH/BPD/26904/2005) and European Commission Marie Curie IEF programme (project 221768) for financial support.

Supporting Information Available

Solubility data for Paracetamol in the presence of different mass ratios of HPMC, and chemical structure of Paracetamol and HPMC molecules. This information is available free of charge via the Internet at <http://pubs.acs.org/>.

References

- (1) *Pulmonary Drug Delivery Systems: Technologies and Global Markets*; Rockville, MD, USA, 2012; p. 222.
- (2) Steckel, H. *International Journal of Pharmaceutics* **2003**, 258, 65–75.
- (3) Martin, G. P.; Zeng, X. M. Pharmaceutical composition for pulmonary delivery. WO/2001/058425, 2001.
- (4) Garside, J.; Mersmann, A.; Nyvlt, J. *Measurement of crystal growth and nucleation rates*; 2nd editio.; IChemE: Rugby, UK, 2002.
- (5) Fujiwara, M.; Nagy, Z. K.; Chew, J. W.; Braatz, R. D. *Journal of Process Control* **2005**, 15, 493–504.
- (6) Grzesiak, A. L.; Matzger, A. J. *Crystal growth & design* **2008**, 8, 347–350.
- (7) Price, C. P.; Grzesiak, A. L.; Matzger, A. J. *Journal of the American Chemical Society* **2005**, 127, 5512–7.
- (8) Lang, M.; Grzesiak, A. L.; Matzger, A. J. *Journal of the American Chemical Society* **2002**, 124, 14834–5.
- (9) Capes, J. S.; Cameron, R. E. *CrystEngComm* **2007**, 9, 84.
- (10) Femi-Oyewo, M. N.; Spring, M. S. *International Journal of Pharmaceutics* **1994**, 112, 17–28.

- (11) Pawar, A.; Paradkar, A. R.; Kadam, S. S.; Mahadik, K. R. *Indian Journal of Pharmaceutical Sciences* **2007**, *69*, 658–664.
- (12) Xie, S.; Poornachary, S. K.; Chow, P. S.; Tan, R. B. H. *Crystal Growth & Design* **2010**, *10*, 3363–3371.
- (13) Davey, R. J.; Blagden, N.; Potts, G. D.; Docherty, R. *Journal of American Chemical Society* **1997**, *7*, 1767–1772.
- (14) Gu, C.-H.; Chatterjee, K.; Young, V.; Grant, D. J. *Journal of Crystal Growth* **2002**, *235*, 471–481.
- (15) Raghavan, S. L.; Trividic, a; Davis, a F.; Hadgraft, J. *International journal of pharmaceutics* **2001**, *212*, 213–21.
- (16) Weiner, M. L.; Kotkoskie, L. A. *Excipient Toxicity and Safety (Drugs and the Pharmaceutical Sciences)*; Marcel Dekker: New York, USA, 2000.
- (17) Chew, C. M.; Ristic, R. I.; Dennehy, R. D.; De Yoreo, J. J. *Crystal Growth & Design* **2004**, *4*, 1045–1052.
- (18) Zarkadas, D. M.; Sirkar, K. K. *Industrial & Engineering Chemistry Research* **2007**, *46*, 2928–2935.
- (19) Granberg, R. A.; Rasmuson, Å. C. *Journal of Chemical & Engineering Data* **2000**, *45*, 478–483.
- (20) Heng, J. Y. Y.; Williams, D. R. *Langmuir : the ACS journal of surfaces and colloids* **2006**, *22*, 6905–9.
- (21) Martino, P. Di; Guyot-Hermann, A.-M.; Conflant, P.; Drache, M.; Guyot, J.-C. *International Journal of Pharmaceutics* **1996**, *128*, 1–8.
- (22) Nichols, G.; Frampton, C. S. *Journal of pharmaceutical sciences* **1998**, *87*, 684–93.
- (23) Thompson, C.; Davies, M. C.; Roberts, C. J.; Tendler, S. J. B.; Wilkinson, M. J. *International journal of pharmaceutics* **2004**, *280*, 137–150.
- (24) Tian, F.; Baldursdottir, S.; Rantanen, J. *Molecular Pharmaceutics* **2009**, *6*, 202–210.
- (25) Sahoo, S.; Chakraborti, C. K.; Behera, P. K. *International Journal of Applied Pharmaceutics* **2012**, *4*.
- (26) Myerson, A. *Handbook of Industrial Crystallization*; Myerson, A., Ed.; Butterworth Heinemann: Boston, USA, 2001.
- (27) Mullin, J.W. *Industrial Crystallization*. Butterworth- Heinemann: London, 1993.

Tables

Table 1. Induction times detected by naked eye, t_{ind} , for batch cooling crystallisation of Paracetamol with HPMC under different nucleation conditions

Run	Wall material	Water-air interface	Mixing	HPMC concentration (w/w)	t_{ind} (min)
1	Glass	Yes	Yes	0.00%	1.7
2	Glass	Yes	Yes	0.10%	4.0
3	Glass	No	Yes	0.10%	9.5
4	LLDPE	Yes	Yes	0.10%	4.4
5	LLDPE	No	Yes	0.10%	10.5
6	LLDPE	Yes	No	0.10%	15.2
7	LLDPE	No	No	0.10%	20.5

Figures list

Figure 1. Experimental setup used in the batch cooling crystallisation experiments.

Figure 2. Real-time profiles temperature and relative solution transmittance (or turbidity) in the vessel during batch cooling crystallisation. For clarity, only HPMC concentrations of 0%, 0.1%, 0.4% and 0.8% w/w were shown.

(a)

(b)

(c)

Figure 3. Effect of initial HPMC concentration on (a) induction time, t_{ind} crystal growth time, t_G and maximum rate of generation solution cloudiness, R_c as determined from turbidity plots in Figure 2; (b) crystal size distribution of dried crystals, and (c) final product yield, for 45 min of cooling. For more details calculating t_{ind} , t_G and R_c in (a) see text. The product yield expected from the solubility data of Granberg&Rasmuson¹⁹ was 73.5% w/w, which is plotted in (c) as a guideline.

Figure 4. Crystal size distribution for Paracetamol crystallised in 0% w/w and 0.1% w/w of HPMC based on (a) volume and (b) frequency. SEM images of Paracetamol samples crystallised in (c) 0% w/w HPMC and (d) 0.1% w/w HPMC. Note the different scale bars used in (c) and (d).

Figure 5. (a) XRD patterns and (b) DSCs for Paracetamol crystallised in 0% w/w and 0.1% w/w of HPMC.

Figure 6. SEM images of Paracetamol crystallised in the presence of (a) 0.1% w/w, (b) 0.3% w/w, (c) 0.7% w/w and (d) 0.8% w/w of HPMC showing microporosity in crystal's surface.

For Table of Contents Only

HPMC as a novel tool for isothermal solution crystallisation of micronized ParacetamolNuno M Reis^{a,b,‡}, Zizheng K Liu^a, Cassilda M Reis^a, and Malcolm R Mackley^a^a*Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK*^b*Department of Chemical Engineering, Loughborough University, Loughborough LE11 3TU, UK*

Micronized Paracetamol crystals were directly produced from solution crystallisation in water by quickly dropping the temperature in the presence of 0.1-0.8% w/w of HPMC. The polymer reduced the solubility of Paracetamol and delayed the onset of nucleation beyond the cooling time of the vessel, consequently allowing to produce fine crystals with sharp CSDs.

[‡] Corresponding author: Phone +44 (0) 1509 222 505; Fax +44 (0) 1509 223 923; e-mail n.m.reis@lboro.ac.uk